Genetics and adverse events with irinotecan treatment: what do we know?

被引：3
作者：
Paez, David [1 ,2 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] CIBERER, U705, Barcelona, Spain
来源：
PHARMACOGENOMICS | 2019年 / 20卷 / 06期
关键词：
INDUCED NEUTROPENIA; CHEMOTHERAPY; GENOTYPE; POLYMORPHISMS; COMBINATION; BEVACIZUMAB; THERAPY; CANCER;
D O I：
10.2217/pgs-2019-0012
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：393 / 395
页数：3
相关论文
共 20 条
  • [1] The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
    Dias, M. M.
    Pignon, J-P
    Karapetis, C. S.
    Boige, V.
    Glimeliuss, B.
    Kweekel, D. M.
    Lara, P. N.
    Laurent-Puig, P.
    Martinez-Balibrea, E.
    Paez, D.
    Punt, C. J. A.
    Redman, M. W.
    Toffoli, G.
    Wadelius, M.
    McKinnon, R. A.
    Sorich, M. J.
    [J]. PHARMACOGENOMICS JOURNAL, 2014, 14 (05) : 424 - 431
  • [2] Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen):: A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer
    Ducreux, M
    Ychou, M
    Seitz, JF
    Bonnay, M
    Bexon, A
    Armand, JP
    Mahjoubi, M
    Méry-Mignard, D
    Rougier, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2901 - 2908
  • [3] Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer
    Fuchs, CS
    Moore, MR
    Harker, G
    Villa, L
    Rinaldi, D
    Hecht, JR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 807 - 814
  • [4] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
    Han, Fei-fei
    Guo, Chang-long
    Yu, Dan
    Zhu, Jin
    Gong, Li-li
    Li, Guang-run
    Lv, Ya-li
    Liu, He
    An, Guang-yu
    Liu, Li-hong
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 779 - 788
  • [5] A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
    Henricks, Linda M.
    Lunenburg, Carin A. T. C.
    de Man, Femke M.
    Meulendijks, Didier
    Frederix, Geert W. J.
    Kienhuis, Emma
    Creemers, Geert-Jan
    Baars, Arnold
    Dezentje, Vincent O.
    Imholz, Alexander L. T.
    Jeurissen, Frank J. F.
    Portielje, Johanna E. A.
    Jansen, Rob L. H.
    Hamberg, Paul
    ten Tije, Albert J.
    Droogendijk, Helga J.
    Koopman, Miriam
    Nieboer, Peter
    van de Poel, Marlene H. W.
    Mandigers, Caroline M. P. W.
    Rosing, Hilde
    Beijnen, Jos H.
    van Werkhoven, Erik
    van Kuilenburg, Andre B. P.
    van Schaik, Ron H. N.
    Mathijssen, Ron H. J.
    Swen, Jesse J.
    Gelderblom, Hans
    Cats, Annemieke
    Guchelaar, Henk-Jan
    Schellens, Jan H. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 107 : 60 - 67
  • [6] DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
    Henricks, Linda M.
    Lunenburg, Carin A. T. C.
    de Man, Femke M.
    Meulendijks, Didier
    Frederix, Geert W. J.
    Kienhuis, Emma
    Creemers, Geert-Jan
    Baars, Arnold
    Dezentje, Vincent O.
    Imholz, Alexander L. T.
    Jeurissen, Frank J. F.
    Portielje, Johanna E. A.
    Jansen, Rob L. H.
    Hamberg, Paul
    ten Tije, Albert J.
    Droogendijk, Helga J.
    Koopman, Miriam
    Nieboer, Peter
    van de Poel, Marlene H. W.
    Mandigers, Caroline M. P. W.
    Rosing, Hilde
    Beijnen, Jos H.
    van Werkhoven, Erik
    van Kuilenburg, Andre B. P.
    van Schaik, Ron H. N.
    Mathijssen, Ron H. J.
    Swen, Jesse J.
    Gelderblom, Hans
    Cats, Annemieke
    Guchelaar, Henk-Jan
    Schellens, Jan H. M.
    [J]. LANCET ONCOLOGY, 2018, 19 (11) : 1459 - 1467
  • [7] UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters
    Hoskins, Janelle M.
    Goldberg, Richard M.
    Qu, Pingping
    Ibrahim, Joseph G.
    McLeod, Howard L.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (17) : 1290 - 1295
  • [8] Irinogenetics and UGT1A:: From genotypes to haplotypes
    Innocenti, F
    Ratain, MJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (06) : 495 - 500
  • [9] Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
    Innocenti, F
    Undevia, SD
    Iyer, L
    Chen, PX
    Das, S
    Kocherginsky, M
    Karrison, T
    Janisch, L
    Ramírez, J
    Rudin, CM
    Vokes, EE
    Ratain, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1382 - 1388
  • [10] A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
    Marcuello, E.
    Paez, D.
    Pare, L.
    Salazar, J.
    Sebio, A.
    del Rio, E.
    Baiget, M.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 53 - 57
12